FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981496445> ?p ?o ?g. }

• W2981496445 endingPage "331" @default.
• W2981496445 startingPage "321" @default.
• W2981496445 abstract "Patients with chronic obstructive pulmonary disease (COPD) and suboptimal peak inspiratory flow rate (sPIFR) may not benefit optimally from dry powder inhalers (DPI) because of inadequate inspiratory flow. Nebulized bronchodilators may provide a better alternative. We compared bronchodilation with the long-acting muscarinic antagonist (LAMA) revefenacin for nebulization versus the DPI LAMA tiotropium, in patients with COPD and sPIFR (< 60 L/min against the resistance of Diskus®).This was a randomized, double-blind, double-dummy, 28-day Phase 3b study in patients with COPD enrolled based on sPIFR. The primary endpoint was trough forced expiratory volume in 1 second (FEV1) on Day 29 for revefenacin for nebulization versus tiotropium HandiHaler® DPI.We enrolled 206 patients with mean (standard deviation) age, 65 (8) years; percent predicted FEV1, 37 (16)%; PIFR, 45 (12) L/min. In the intent-to-treat (ITT) population, revefenacin improved trough FEV1 from baseline; however, the difference versus tiotropium was not significant (least squares [LS] mean difference [standard error], 17.0 [22.4] mL, P=0.4461). In a prespecified analysis of patients with FEV1 < 50% predicted, revefenacin produced an LS mean difference (95% confidence interval [CI]), 49.1 (6.3-91.9) mL in trough FEV1 and 103.5 (7.7-199.3) mL in forced vital capacity versus tiotropium. Revefenacin produced >100 mL increase in FEV1 in 41.6% versus 34.4% of patients with tiotropium in ITT and 41.4% versus 25.7% of patients in FEV1 < 50% predicted populations.Revefenacin did not produce significant improvements in FEV1 versus tiotropium in the ITT population, but increased trough FEV1 in patients with FEV1 < 50% predicted and sPIFR. Clinical Trial Registration (www.Clinicaltrials.gov): Study 0149 (NCT03095456)." @default.
• W2981496445 created "2019-11-01" @default.
• W2981496445 creator A5018217171 @default.
• W2981496445 creator A5024992973 @default.
• W2981496445 creator A5026644072 @default.
• W2981496445 creator A5061651945 @default.
• W2981496445 creator A5084110999 @default.
• W2981496445 creator A5091161510 @default.
• W2981496445 date "2019-01-01" @default.
• W2981496445 modified "2023-10-12" @default.
• W2981496445 title "Nebulized Versus Dry Powder Long-Acting Muscarinic Antagonist Bronchodilators in Patients With COPD and Suboptimal Peak Inspiratory Flow Rate" @default.
• W2981496445 cites W2029276834 @default.
• W2981496445 cites W2056648907 @default.
• W2981496445 cites W2065198154 @default.
• W2981496445 cites W2090085954 @default.
• W2981496445 cites W2105234929 @default.
• W2981496445 cites W2105726389 @default.
• W2981496445 cites W2113026917 @default.
• W2981496445 cites W2132445095 @default.
• W2981496445 cites W2141416635 @default.
• W2981496445 cites W2144455511 @default.
• W2981496445 cites W2145457986 @default.
• W2981496445 cites W2145746547 @default.
• W2981496445 cites W2174826642 @default.
• W2981496445 cites W2536520001 @default.
• W2981496445 cites W2606684647 @default.
• W2981496445 cites W2613757726 @default.
• W2981496445 cites W2734544219 @default.
• W2981496445 cites W2758140560 @default.
• W2981496445 cites W2770700164 @default.
• W2981496445 cites W2915558721 @default.
• W2981496445 cites W2941013947 @default.
• W2981496445 cites W4292528167 @default.
• W2981496445 doi "https://doi.org/10.15326/jcopdf.6.4.2019.0137" @default.
• W2981496445 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7006701" @default.
• W2981496445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31647854" @default.
• W2981496445 hasPublicationYear "2019" @default.
• W2981496445 type Work @default.
• W2981496445 sameAs 2981496445 @default.
• W2981496445 citedByCount "14" @default.
• W2981496445 countsByYear W29814964452019 @default.
• W2981496445 countsByYear W29814964452021 @default.
• W2981496445 countsByYear W29814964452022 @default.
• W2981496445 crossrefType "journal-article" @default.
• W2981496445 hasAuthorship W2981496445A5018217171 @default.
• W2981496445 hasAuthorship W2981496445A5024992973 @default.
• W2981496445 hasAuthorship W2981496445A5026644072 @default.
• W2981496445 hasAuthorship W2981496445A5061651945 @default.
• W2981496445 hasAuthorship W2981496445A5084110999 @default.
• W2981496445 hasAuthorship W2981496445A5091161510 @default.
• W2981496445 hasBestOaLocation W29814964451 @default.
• W2981496445 hasConcept C126322002 @default.
• W2981496445 hasConcept C164705383 @default.
• W2981496445 hasConcept C165637977 @default.
• W2981496445 hasConcept C170493617 @default.
• W2981496445 hasConcept C2776042228 @default.
• W2981496445 hasConcept C2776723954 @default.
• W2981496445 hasConcept C2776780178 @default.
• W2981496445 hasConcept C2776885963 @default.
• W2981496445 hasConcept C2776968687 @default.
• W2981496445 hasConcept C2777419714 @default.
• W2981496445 hasConcept C2777714996 @default.
• W2981496445 hasConcept C2780261241 @default.
• W2981496445 hasConcept C2780911369 @default.
• W2981496445 hasConcept C2781018748 @default.
• W2981496445 hasConcept C2908646376 @default.
• W2981496445 hasConcept C2908647359 @default.
• W2981496445 hasConcept C3018587741 @default.
• W2981496445 hasConcept C42219234 @default.
• W2981496445 hasConcept C44249647 @default.
• W2981496445 hasConcept C55520419 @default.
• W2981496445 hasConcept C71924100 @default.
• W2981496445 hasConcept C99454951 @default.
• W2981496445 hasConceptScore W2981496445C126322002 @default.
• W2981496445 hasConceptScore W2981496445C164705383 @default.
• W2981496445 hasConceptScore W2981496445C165637977 @default.
• W2981496445 hasConceptScore W2981496445C170493617 @default.
• W2981496445 hasConceptScore W2981496445C2776042228 @default.
• W2981496445 hasConceptScore W2981496445C2776723954 @default.
• W2981496445 hasConceptScore W2981496445C2776780178 @default.
• W2981496445 hasConceptScore W2981496445C2776885963 @default.
• W2981496445 hasConceptScore W2981496445C2776968687 @default.
• W2981496445 hasConceptScore W2981496445C2777419714 @default.
• W2981496445 hasConceptScore W2981496445C2777714996 @default.
• W2981496445 hasConceptScore W2981496445C2780261241 @default.
• W2981496445 hasConceptScore W2981496445C2780911369 @default.
• W2981496445 hasConceptScore W2981496445C2781018748 @default.
• W2981496445 hasConceptScore W2981496445C2908646376 @default.
• W2981496445 hasConceptScore W2981496445C2908647359 @default.
• W2981496445 hasConceptScore W2981496445C3018587741 @default.
• W2981496445 hasConceptScore W2981496445C42219234 @default.
• W2981496445 hasConceptScore W2981496445C44249647 @default.
• W2981496445 hasConceptScore W2981496445C55520419 @default.
• W2981496445 hasConceptScore W2981496445C71924100 @default.
• W2981496445 hasConceptScore W2981496445C99454951 @default.
• W2981496445 hasIssue "4" @default.
• W2981496445 hasLocation W29814964451 @default.
• W2981496445 hasLocation W29814964452 @default.

• next